en · de · es · fr · pt
bpc-157-notes.peptides8425.com › Wiki › Origin And Peptide Identity — What the Evidence Shows

Origin And Peptide Identity — What the Evidence Shows

By Editorial Desk · published 2026-04-12 · last reviewed 2026-05-09 · Wiki

A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-05-09 and is reviewed periodically as new material appears.

Origin and Peptide Identity

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

How Research Literature Discusses It

Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.

Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.

Bpc-157 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderAssessed by visual inspection under ordinary laboratory lighting
Molecular massApproximately 1419 DaMonoisotopic mass for the fifteen-residue sequence
Solubility classFreely soluble in waterStock solutions commonly prepared in water or aqueous buffer
Typical storage temperature-20 °C or below, desiccatedLyophilized powder; repeated freeze-thaw cycles are usually avoided
Common analytical methodReversed-phase HPLC with UV detectionFrequently paired with mass spectrometry to confirm identity

Identity And Chemical Background

Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.

The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.

Related pages on this site

BPC-157 Handling and Analysis

Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.

Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.

BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.

Further detail

The ABCA subfamily is composed of 12 full transporters split into two subgroups. The first subgroup consists of seven genes that map to six different chromosomes. These are ABCA1, ABCA2, ABCA3, and ABCA4, ABCA7, ABCA12, and ABCA13. The other subgroup consists of ABCA5 and ABCA6 and ABCA8, ABCA9 and ABCA10. A8-10. All of subgroup 2 is organized into a head to tail cluster of chromosomes on chromosome 17q24. Genes in this second subgroup are distinguished from ABCA1-like genes by having 37-38 exons as opposed to the 50 exons in ABCA1. The ABCA1 subgroup is implicated in the development of genetic diseases. In the recessive Tangier's disease, the ABCA1 protein is mutated. Also, the ABCA4 maps to a region of chromosome 1p21 that contains the gene for Stargardt's disease. This gene is found to be highly expressed in rod photoreceptors and is mutated in Stargardt's disease, recessive retinitis pigmentism, and the majority of recessive cone-rod dystrophy.

== In the environment == The long half-life of technetium-99 and its ability to form an anionic species make it (along with 129I) a major concern when considering long-term disposal of high-level radioactive waste. Many of the processes designed to remove fission products from medium-active process streams in reprocessing plants are designed to remove cationic species like caesium (e.g., 137Cs, 134Cs) and strontium (e.g., 90Sr). Hence the pertechnetate escapes through these treatment processes. Disposal options favor burial in geologically stable rock. The primary danger with such a course is that the waste is likely to come into contact with water, which could leach radioactive contamination into the environment. The natural cation-exchange capacity of soils tends to immobilize plutonium, uranium, and caesium cations. However, the anion-exchange capacity is usually much smaller, so minerals are less likely to adsorb the pertechnetate and iodide anions, leaving them mobile in the soil. For this reason, the environmental chemistry of technetium is an active area of research.

==== Role of the brain ==== The brain stem can control food intake, because it contains neural circuits that detect hunger and satiety signals from other parts of the body. The brain stem's involvement of food intake has been researched using rats. Rats that have had the motor neurons in the brain stem disconnected from the neural circuits of the cerebral hemispheres (decerebration), are unable to approach and eat food. Instead, they must obtain their food in a liquid form. This research shows that the brain stem does in fact play a role in eating. There are two peptides in the hypothalamus that produce hunger, melanin concentrating hormone (MCH) and orexin. MCH plays a bigger role in producing hunger. In mice, MCH stimulates feeding and a mutation causing the overproduction of MCH led to overeating and obesity. Orexin plays a greater role in controlling the relationship between eating and sleeping. Other peptides in the hypothalamus that induce eating are neuropeptide Y (NPY) and agouti-related protein (AGRP). Satiety in the hypothalamus is stimulated by leptin. Leptin targets the receptors on the arcuate nucleus and suppresses the secretion of MCH and orexin. The arcuate nucleus also contains two more peptides that suppress hunger. The first one is cocaine- and amphetamine-regulated transcript (CART), the second is α-MSH (α-melanocyte-stimulating hormone).

The statue of Augustus of Prima Porta was discovered within the Villa of Livia in 1863. Little is known about the discovery itself and its immediate aftermath, as the incomplete archaeological journals leave ambiguous evidence for modern historians. The statue was first publicized by the German archaeologist Wilhelm Henzen in 1863 in the Bulletino dell'Instituto di Corrispondenza Archaeologica. The exact location of the statue within the villa is unknown. Suggested sites are the underground complex, a placement near a staircase, the villa's atrium, or in a laurel grove on the southeast corner of Prima Porta hill. Scholars have stated that the last one is relatively unconvincing compared with the first three. The theory that Augustus's statue was found in the underground complex of the villa is based on a hypothesis that Augustus holds a laurel branch instead of a spear in his left hand. Scholars have noted that if this hypothesis is correct, then Villa of Livia must have been decorated with laurel groves and that the reason of the decoration is the omen of the gallina alba (Latin: white hen). Recent excavations have discovered the remnants of pots used to plant laurel on the edge of the Prima Porta hill in front of the underground complex, which Reeder believes suggests the possibility of the existence of laurel groves in the villa and makes it likely that the statue was located in the underground complex.

These two drugs work synergistically and were found to be more effective than either drug alone. The development of nanotechnology and molecular biology has provided the improvement of nanomaterials with specific properties which are now able to overcome the weaknesses of traditional disease diagnostic and therapeutic procedures. In recent years, more attention has been devoted to designing and the development of new methods for realizing sustained release of diverse drugs. Since each drug has a plasma level above which is toxic and below which is ineffective and in conventional drug delivery, the drug concentration in the blood rises quickly and then declines, the main aim of an ideal drug delivery system (DDS) is to maintain the drug within a desired therapeutic range after a single dose, and/or target the drug to a specific region while simultaneously lowering the systemic levels of the drug. Graphene–based materials such as graphene oxide (GO) have considerable potential for several biological applications including the development of new drug release system. GOs are an abundance of functional groups such as hydroxyl, epoxy, and carboxyl on its basal surface and edges that can be also used to immobilize or load various biomolecules for biomedical applications. On the other side, biopolymers have frequently been used as raw materials for designing drug delivery formulations owing to their excellent properties, such as non-toxicity, biocompatibility, biodegradability and environmental sensitivity, etc.

Sources: en.wikipedia.org

Background from the literature

=== Mice === Mouse FPR receptors localize to chromosome 17A3.2 in the following order: Fpr1, Fpr-rs2 (or fpr2), Fpr-rs1 (or LXA4R), Fpr-rs4, Fpr-rs7, Fpr-rs7, Fpr-rs6, and Fpr-rs3; Pseudogenes ψFpr-rs2 and ψFpr-rs3 (or ψFpr-rs5) lie just after Fpr-rs2 and Fpr-rs1, respectively. All of the active mouse FPR receptors have ≥50% amino acid sequence identity with each other as well as with the three human FPR receptors. Based on its predominantly intracellular distribution, mFpr-rs1 correlates, and therefore may share functionality, with human FPR3; However, the large number of mouse compared to human FPR receptors makes it difficult to extrapolate human FPR functions based on genetic (e.g. gene knockout or forced overexpression) or other experimental manipulations of the FPR receptors in mice.

Bones are surrounded by a membrane known as the periosteum (Greek περῐ́ (perí), around; Greek ὀστέον (ostéon), bone), and comprise multiple layers, depending on the type of bone, including yellow and red bone marrow, spongy bone, and the endosteum. There are five general classifications of bones: Long bones are characterized by a shaft known as the diaphysis, which is much longer than its width, and an epiphysis (Greek ἐπι- (epi-) upon, outside, over), a rounded head at each end of the shaft, connected to the diaphysis by the epiphyseal plate. They are made up mostly of compact bone, with lesser amounts of marrow, located within the medullary cavity, and areas of spongy, cancellous bone at the ends of the bones. Short bones are roughly cube-shaped, and have only a thin layer of compact bone surrounding a spongy interior. Short bones provide stability and support as well as some limited motion. Flat bones are thin and generally curved, with two parallel layers of compact bone sandwiching a layer of spongy bone. Sesamoid bones are bones embedded in tendons. Since they act to hold the tendon further away from the joint, the angle of the tendon is increased and thus the leverage of the muscle is increased. Irregular bones do not fit into the above categories. They consist of thin layers of compact bone surrounding a spongy interior. As implied by the name, their shapes are irregular and complicated. Often this irregular shape is due to their many centers of ossification or because they contain bony sinuses.

=== Size and other body parts === There is no correlation between shoe size and stretched penis size. Nose size was highly related to stretched penile length in Japanese male cadavers. There may be a link between the malformation of the genitalia and the human limbs. The development of the penis in an embryo is controlled by some of the same Hox genes (in particular HOXA13 and HOXD13) as those that control the development of the limbs. Mutations of some Hox genes that control the growth of limbs cause malformed genitalia (hand–foot–genital syndrome).

== Mechanism == The interfacing mechanism is contained inside a common EI source, like that found in any GC-MS system. The liquid phase from a nano HPLC column is admitted from the capillary column port, where the connection tubing and the nebulizer are first introduced and sealed to prevent vacuum loss. The mechanism is based on the formation of an aerosol in high-vacuum conditions, followed by a quick droplet desolvation and final vaporization of the solute prior to the ionization. The completion of the process is quick and complete and reduces chances of thermal decomposition as reported in the Figure, where a scheme of the interface is shown. The core of the interface is represented by the micro-nebulizer. The nebulizer tip protrudes into the ion source so that the spray expansion is completely contained inside the ion volume. The eluate emerges as liquid phase at a flow rate of 300-500 nL/min, and any premature in-tube solvent evaporation is prevented by a convenient thermal insulation of the nebulizer and the connecting tubing from the surrounding source heat. The high temperature of the ion source, between 300 and 400°C, has a double function: to compensate for the latent heat of vaporization during the droplet desolvation, and to convert the solute into the gas phase. If all components of this simple interface are correctly placed and sized, then each substance separated by the nano-column is smoothly converted into the gas phase, the peak profile is nicely reproduced, and high quality mass spectra are generated.

==== Prognosis and treatment ==== Untreated necrotic pulp may result in further complications, such as infection, fever, swelling, abscesses and bone loss. Two treatment options are available for pulpal necrosis.

Sources: en.wikipedia.org

Reference notes

Rindo Azami (阿左美 竜胆, Azami Rindō) Voiced by: Taku Yashiro (Japanese); Lee George (English) The Agent of Autumn's Guard. He treats his job like a business, without letting his emotions get in the way. Those around him don't see it that way. He doesn't realize it, but he's overprotective of Nadeshiko.

Dietary supplement companies aggressively promote NMN products claiming these benefits. NMN is a precursor to NAD+ biosynthesis, and dietary NMN supplementation has been shown to increase NAD+ concentrations and thus has the potential to mitigate aging-related disorders such as oxidative stress, DNA damage, neurodegeneration, and inflammatory responses. The potential benefits and risks of NMN supplementation as of 2023 are currently under study. Life extension Anti-aging movement

=== Accolades === In 2004, IGN named Bloodlines the Best PC RPG of that year and GameSpy called the "Ocean House Hotel" quest the Level of the Year. In 2005, Computer Gaming World called it the Role Playing Game of 2004, saying that it offered "a deep, balanced character creation system, a truckload of interesting quests, a good story and great NPCs to interact with." Computer Games Magazine nominated Bloodlines for its 2004 "Best Writing" award; the award went to Half-Life 2. During the 8th Annual Interactive Achievement Awards, the Academy of Interactive Arts & Sciences nominated Bloodlines for "Computer Role-Playing Game of the Year".

=== Weight and blood pressure === Empagliflozin causes moderate reductions in blood pressure and body weight. These effects are likely due to the excretion of glucose in the urine and a slight increase in urinary sodium excretion. In clinical trials, participants with type 2 diabetes taking empagliflozin with other diabetic medications lost an average of 2% of their baseline body weight. Empagliflozin use has been associated with clinically meaningful weight loss, with a higher proportion of individuals achieving weight loss greater than 5% of their baseline weight compared to placebo. The degree of weight loss may vary depending on the dosage (10mg or 25mg). While weight loss can contribute to improved glycaemic control, the primary glucose-lowering effect of empagliflozin occurs independently through increased urinary glucose excretion. The same extent of weight loss was also observed in a study with heart failure patients taking empagliflozin. Empagliflozin has been shown to reduce systolic blood pressure by 3 to 5 millimeters of mercury (mmHg) without changes in pulse rate. A greater percentage of people with uncontrolled blood pressure at baseline, achieved controlled blood pressure (i.e. systolic blood pressure <130 mmHg and diastolic blood pressure <80 mmHg) after taking empagliflozin at 24 weeks. The effects on blood pressure and body weight are generally viewed as favorable, as many people with type 2 diabetes have high blood pressure or are overweight or obese.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157 chemically?

It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.

How is the material usually supplied?

It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.

Does the abbreviation stand for a chemical name?

The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.

Has BPC-157 been tested in humans?

Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.

Network